Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy
Juliane Gust(University of Washington), Rebecca Gardner(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Robert F. Hevner(University of California San Diego), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Robert B. Futrell(Seattle Children's Hospital), Danielle N. Gamble(Seattle Children's Hospital), Virginia E. Duncan(University of Alabama at Birmingham), Olivia Finney(Seattle Children's Hospital), Hedieh Khalatbari(Seattle Children's Hospital), Daniel Li(Juno Therapeutics (Germany)), Roxana Hicks(Seattle Children's Hospital), Hannah Brakke(Seattle Children's Hospital), Gisele E. Ishak(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital)
Cited by 191
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754